Panelists discuss insights from the MARIPOSA study on first-line treatment options for EGFR-mutant metastatic non–small cell lung cancer (NSCLC), highlighting the efficacy of amivantamab-lazertinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results